AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
6.12 USD -3.32% Intraday chart for AngioDynamics, Inc. -10.00% -21.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Inflation Data, -2- DJ
Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target MT
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device MT
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System DJ
Transcript : AngioDynamics, Inc., Q3 2024 Earnings Call, Apr 04, 2024
AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment DJ
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q3 Revenue $66M MT
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 CI
AngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024 CI
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024 CI
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE CI
North American Morning Briefing : Focus Turns to -2- DJ
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate MT
AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co DJ
AngioDynamics Sells Two Product Lines to Spectrum Vascular for up to $45 Million Cash; Shares Up in Pre-Bell Trading MT
Spectrum Vascular acquired PICC and Midline Product Portfolios from AngioDynamics, Inc. for $45 million. CI
Angiodynamics, Inc. Announces Board Changes CI
AngioDynamics Receives FDA Clearance for Auryon XL Radial Access Catheter MT
Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease CI
AngioDynamics, Inc. Announces Dennis Meteny to Retire as A Member of the Board of Directors, Member of the Compensation Committee and Chair of the Audit Committee, Effective January 31, 2024 CI
Transcript : AngioDynamics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:00 AM
Raymond James Adjusts Price Target on AngioDynamics to $10 From $12, Maintains Outperform Rating MT
HC Wainwright Adjusts Price Target on AngioDynamics to $18 From $20, Keeps Buy Rating MT
Sector Update: Health Care Stocks Retreat Late Afternoon MT
AngioDynamics Shares Fall After Q2 Swing to Adjusted Loss; Revenue Drops MT
Chart AngioDynamics, Inc.
More charts
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
6.12 USD
Average target price
13.5 USD
Spread / Average Target
+120.59%
Consensus
  1. Stock Market
  2. Equities
  3. ANGO Stock
  4. News AngioDynamics, Inc.
  5. Earnings Flash (ANGO) ANGIODYNAMICS Posts Q3 Revenue $74M, vs. Street Est of $76.3M